JP2024501403A - ガンマ－デルタｔ細胞受容体に結合する抗体 - Google Patents

ガンマ－デルタｔ細胞受容体に結合する抗体 Download PDF

Info

Publication number
JP2024501403A
JP2024501403A JP2023532452A JP2023532452A JP2024501403A JP 2024501403 A JP2024501403 A JP 2024501403A JP 2023532452 A JP2023532452 A JP 2023532452A JP 2023532452 A JP2023532452 A JP 2023532452A JP 2024501403 A JP2024501403 A JP 2024501403A
Authority
JP
Japan
Prior art keywords
antibody
seq
set forth
binding region
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501403A5 (https=
Inventor
ウィレム アンリ イダ パーレン，ポール
コーネリス ルーバーズ，ロベルトゥス
デル ヴリット，ヨハネス ジェレ ヴァン
フルシク，デイヴィッド ルジェ
アレクサンダー ゲラルドゥス マリア マチェルセン，ピーター
ウェスターホーフェン，ミキエル ヴァン
アンナ キング，リサ
フェンネマン，フェリックス－レナート
Original Assignee
ラヴァ・セラピューティクス・エヌ・ヴイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラヴァ・セラピューティクス・エヌ・ヴイ filed Critical ラヴァ・セラピューティクス・エヌ・ヴイ
Publication of JP2024501403A publication Critical patent/JP2024501403A/ja
Publication of JP2024501403A5 publication Critical patent/JP2024501403A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023532452A 2020-12-10 2021-12-09 ガンマ－デルタｔ細胞受容体に結合する抗体 Pending JP2024501403A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20213166.0 2020-12-10
EP20213166 2020-12-10
PCT/EP2021/085079 WO2022122973A1 (en) 2020-12-10 2021-12-09 Antibodies that bind gamma-delta t cell receptors

Publications (2)

Publication Number Publication Date
JP2024501403A true JP2024501403A (ja) 2024-01-12
JP2024501403A5 JP2024501403A5 (https=) 2024-12-17

Family

ID=73793117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532452A Pending JP2024501403A (ja) 2020-12-10 2021-12-09 ガンマ－デルタｔ細胞受容体に結合する抗体

Country Status (10)

Country Link
US (1) US20230303694A1 (https=)
EP (1) EP4259660A1 (https=)
JP (1) JP2024501403A (https=)
KR (1) KR20230157933A (https=)
CN (1) CN116888153A (https=)
AU (1) AU2021395439A1 (https=)
CA (1) CA3200826A1 (https=)
IL (1) IL303045A (https=)
MX (1) MX2023006832A (https=)
WO (1) WO2022122973A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
WO2025024780A1 (en) 2023-07-27 2025-01-30 LAVA Therapeutics N.V. Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025128615A1 (en) * 2023-12-12 2025-06-19 Seagen Inc. Multispecific egfr antibodies and use in the treatment of cancer
TW202535922A (zh) * 2023-12-18 2025-09-16 美商思進公司 治療ｅｇｆｒ突變癌症之方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
DK3129404T3 (da) 2014-04-10 2026-04-20 Lava Therapeutics N V Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
EP3792283A1 (en) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RENEE C. G. DE BRUIN ET AL., ONCOIMMUNOLOGY, vol. Vol. 7, No. 1, e1375641, JPN6026002138, 20 October 2017 (2017-10-20), pages 1 - 14, ISSN: 0005778922 *

Also Published As

Publication number Publication date
KR20230157933A (ko) 2023-11-17
US20230303694A1 (en) 2023-09-28
EP4259660A1 (en) 2023-10-18
AU2021395439A1 (en) 2023-06-22
MX2023006832A (es) 2023-08-22
CA3200826A1 (en) 2022-06-16
CN116888153A (zh) 2023-10-13
AU2021395439A9 (en) 2024-09-12
IL303045A (en) 2023-07-01
WO2022122973A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
AU2022223152B2 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
CN113710707B (zh) 结合于psma的重链抗体
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
JP7686571B2 (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
JP2023532807A (ja) Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
JP2024514107A (ja) 抗ｃｄ１９抗体及びｃａｒ－ｔ構造体
US20250230240A1 (en) Variant antibodies that bind gamma-delta t cell receptors
JP2024507937A (ja) Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体
US20250109204A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
EA053202B1 (ru) Антитела, которые связывают гамма-дельта т-клеточные рецепторы
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
KR20250158060A (ko) 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법
EA048596B1 (ru) Антитела, которые связывают psma и гамма-дельта рецепторы т-клеток
EA050049B1 (ru) Антитела к cd19 и car-t-клеточные структуры

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421